Nagao Manabu, Toh Ryuji, Irino Yasuhiro, Nakajima Hideto, Oshita Toshihiko, Tsuda Shigeyasu, Hara Tetsuya, Shinohara Masakazu, Ishida Tatsuro, Hirata Ken-Ichi
Division of Cardiovascular Medicine Kobe University Graduate School of Medicine Japan.
Division of Evidence-Based Laboratory Medicine Kobe University Graduate School of Medicine Japan.
FEBS Open Bio. 2017 Aug 14;7(9):1402-1409. doi: 10.1002/2211-5463.12279. eCollection 2017 Sep.
Low levels of plasma high-density lipoprotein (HDL) cholesterol are associated with an increased risk of heart failure, regardless of the presence or absence of coronary artery disease. However, the direct effects of HDL on failing myocardium have not been fully elucidated. We found that HDL treatment resulted in improved cell viability in H9c2 cardiomyocytes under oxidative stress. This cardioprotective effect of HDL was regulated via the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway. mTOR signaling promotes cell survival through the inactivation of the BCL2-associated agonist of cell death via phosphorylation of ribosomal protein S6 kinase. Modulation of cardiac PI3K/mTOR signaling by HDL could represent a novel therapeutic strategy for heart failure.
无论是否存在冠状动脉疾病,血浆高密度脂蛋白(HDL)胆固醇水平低都与心力衰竭风险增加相关。然而,HDL对衰竭心肌的直接作用尚未完全阐明。我们发现,HDL处理可提高氧化应激下H9c2心肌细胞的细胞活力。HDL的这种心脏保护作用是通过磷脂酰肌醇3激酶(PI3K)/雷帕霉素哺乳动物靶蛋白(mTOR)途径调节的。mTOR信号通过核糖体蛋白S6激酶磷酸化使细胞死亡的BCL2相关激动剂失活来促进细胞存活。HDL对心脏PI3K/mTOR信号的调节可能代表一种治疗心力衰竭的新策略。